Cingulate Announces Private Placement and New Preferred Stock

The latest update is out from Cingulate Inc ( (CING) ).

On January 27, 2026, Cingulate Inc. entered into a securities purchase agreement with a group of accredited investors, including certain company insiders, for a $12 million private placement comprising 2,147,471 common shares, 973 shares of Series A convertible preferred stock and warrants for 1,868,482 common shares, at an effective price of $5.14 per common share (including warrant value). The deal, expected to close by February 2, 2026 subject to customary conditions, will see Falcon Creek gain the right to designate up to two of seven board members, subject to ownership thresholds, while investors are bound by a 180-day lock-up and a 24‑month standstill limiting additional accumulation, activism, and control transactions; Cingulate plans to use the proceeds for working capital and general corporate purposes. In a related step, on January 28, 2026, the company filed a certificate of designation in Delaware establishing the Series A preferred stock, which carries a 12% cumulative annual dividend on its $1,000 stated value, no general voting rights, and an automatic conversion into common stock at $5.04 per share plus accrued dividends once shareholders approve the conversion, potentially reshaping the company’s capital structure and diluting existing holders over time, while the separately executed warrant grants investors additional upside leverage at a $5.04 exercise price.

The most recent analyst rating on (CING) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.

Spark’s Take on CING Stock

According to Spark, TipRanks’ AI Analyst, CING is a Neutral.

The score is held back primarily by weak financial performance (no revenue, widening losses, and persistent cash burn) and limited valuation signal due to negative earnings. Technicals are moderately positive (price above major moving averages with neutral RSI), while recent corporate events improve liquidity and advance the NDA/commercialization path but still add financing dependence and regulatory uncertainty.

To see Spark’s full report on CING stock, click here.

More about Cingulate Inc

Cingulate Inc. operates in the biopharmaceutical sector, focusing on the development and commercialization of therapies using its proprietary drug delivery technologies, with its capital markets activity centered on funding ongoing operations and general corporate purposes through equity and equity-linked securities.

Average Trading Volume: 189,171

Technical Sentiment Signal: Buy

Current Market Cap: $37.53M

For an in-depth examination of CING stock, go to TipRanks’ Overview page.